Mainz Biomed B.V. (MYNZ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on the stock and has a $14.00 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Michael Okunewitch has given his Buy rating due to a combination of factors surrounding Mainz Biomed B.V.’s promising advancements in cancer diagnostics. The company has initiated a feasibility study for a new blood-based pancreatic cancer test, PancAlert, which utilizes a biomarker panel licensed from Liquid Biosciences. This test has shown impressive results, achieving 95% sensitivity and 98% specificity, indicating its potential as a leading diagnostic tool.
Additionally, Mainz Biomed is progressing with its eAArly DETECT 2 study for colorectal cancer screening, with interim data expected by the end of summer 2025. The company’s recent public offering has also strengthened its financial position, raising $4.0 million. These developments, combined with the significant unmet need for effective pancreatic cancer screening, underpin Okunewitch’s optimistic outlook for Mainz Biomed’s stock.